nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—muscle cancer	0.627	1	CtDrD
Gefitinib—CYP1A1—Dacarbazine—muscle cancer	0.0368	0.165	CbGbCtD
Gefitinib—ABCG2—Dactinomycin—muscle cancer	0.0345	0.155	CbGbCtD
Gefitinib—ABCG2—Vincristine—muscle cancer	0.0213	0.0956	CbGbCtD
Gefitinib—ABCG2—Etoposide—muscle cancer	0.0195	0.0876	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—muscle cancer	0.0133	0.0597	CbGbCtD
Gefitinib—ABCG2—Methotrexate—muscle cancer	0.0129	0.0579	CbGbCtD
Gefitinib—ABCB1—Dactinomycin—muscle cancer	0.0124	0.056	CbGbCtD
Gefitinib—CYP3A5—Vincristine—muscle cancer	0.0118	0.053	CbGbCtD
Gefitinib—CYP3A5—Etoposide—muscle cancer	0.0108	0.0485	CbGbCtD
Gefitinib—ALB—Methotrexate—muscle cancer	0.00887	0.0399	CbGbCtD
Gefitinib—ABCB1—Vincristine—muscle cancer	0.00767	0.0345	CbGbCtD
Gefitinib—ABCB1—Etoposide—muscle cancer	0.00702	0.0316	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—muscle cancer	0.00479	0.0215	CbGbCtD
Gefitinib—ABCB1—Methotrexate—muscle cancer	0.00464	0.0209	CbGbCtD
Gefitinib—CYP3A4—Vincristine—muscle cancer	0.00459	0.0207	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—muscle cancer	0.00451	0.0203	CbGbCtD
Gefitinib—CYP3A4—Etoposide—muscle cancer	0.00421	0.0189	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—muscle cancer	0.00287	0.0129	CbGbCtD
Gefitinib—SBK1—tendon—muscle cancer	0.0011	0.0304	CbGeAlD
Gefitinib—ERBB3—embryo—muscle cancer	0.000988	0.0274	CbGeAlD
Gefitinib—CHEK2—tendon—muscle cancer	0.000954	0.0265	CbGeAlD
Gefitinib—SBK1—head—muscle cancer	0.000939	0.026	CbGeAlD
Gefitinib—CHEK2—bone marrow—muscle cancer	0.000924	0.0256	CbGeAlD
Gefitinib—SBK1—testis—muscle cancer	0.000907	0.0251	CbGeAlD
Gefitinib—HIPK4—testis—muscle cancer	0.000897	0.0249	CbGeAlD
Gefitinib—CHEK2—vagina—muscle cancer	0.000886	0.0245	CbGeAlD
Gefitinib—Vandetanib—VEGFA—muscle cancer	0.000798	1	CrCbGaD
Gefitinib—CHEK2—testis—muscle cancer	0.00079	0.0219	CbGeAlD
Gefitinib—ERBB3—renal system—muscle cancer	0.000748	0.0207	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—muscle cancer	0.000739	0.0205	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—muscle cancer	0.000739	0.0205	CbGeAlD
Gefitinib—EPHA6—head—muscle cancer	0.000734	0.0203	CbGeAlD
Gefitinib—MKNK2—renal system—muscle cancer	0.000711	0.0197	CbGeAlD
Gefitinib—EPHA6—testis—muscle cancer	0.000709	0.0196	CbGeAlD
Gefitinib—MAP3K19—head—muscle cancer	0.000667	0.0185	CbGeAlD
Gefitinib—MAP3K19—testis—muscle cancer	0.000644	0.0179	CbGeAlD
Gefitinib—MKNK2—cardiac atrium—muscle cancer	0.000637	0.0177	CbGeAlD
Gefitinib—MKNK1—cardiac atrium—muscle cancer	0.000629	0.0174	CbGeAlD
Gefitinib—CSNK1E—tendon—muscle cancer	0.000605	0.0168	CbGeAlD
Gefitinib—IRAK4—tendon—muscle cancer	0.000596	0.0165	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vincristine—muscle cancer	0.000595	0.192	CbGdCrCtD
Gefitinib—STK10—renal system—muscle cancer	0.000578	0.016	CbGeAlD
Gefitinib—IRAK4—bone marrow—muscle cancer	0.000577	0.016	CbGeAlD
Gefitinib—CSNK1E—vagina—muscle cancer	0.000561	0.0156	CbGeAlD
Gefitinib—ERBB3—Podofilox—Etoposide—muscle cancer	0.000556	0.179	CbGdCrCtD
Gefitinib—IRAK1—tendon—muscle cancer	0.000555	0.0154	CbGeAlD
Gefitinib—MKNK2—tendon—muscle cancer	0.000555	0.0154	CbGeAlD
Gefitinib—IRAK4—vagina—muscle cancer	0.000553	0.0153	CbGeAlD
Gefitinib—MKNK2—bone marrow—muscle cancer	0.000538	0.0149	CbGeAlD
Gefitinib—IRAK1—bone marrow—muscle cancer	0.000538	0.0149	CbGeAlD
Gefitinib—MKNK1—bone marrow—muscle cancer	0.000531	0.0147	CbGeAlD
Gefitinib—EGFR—testis—muscle cancer	0.000521	0.0144	CbGeAlD
Gefitinib—CSNK1E—head—muscle cancer	0.000519	0.0144	CbGeAlD
Gefitinib—MKNK2—vagina—muscle cancer	0.000515	0.0143	CbGeAlD
Gefitinib—IRAK4—head—muscle cancer	0.000511	0.0142	CbGeAlD
Gefitinib—MKNK1—vagina—muscle cancer	0.000509	0.0141	CbGeAlD
Gefitinib—CSNK1E—testis—muscle cancer	0.000501	0.0139	CbGeAlD
Gefitinib—ERBB3—head—muscle cancer	0.0005	0.0139	CbGeAlD
Gefitinib—IRAK4—testis—muscle cancer	0.000493	0.0137	CbGeAlD
Gefitinib—ERBB3—testis—muscle cancer	0.000483	0.0134	CbGeAlD
Gefitinib—MKNK2—head—muscle cancer	0.000476	0.0132	CbGeAlD
Gefitinib—MKNK1—head—muscle cancer	0.00047	0.013	CbGeAlD
Gefitinib—MAP2K5—cardiac atrium—muscle cancer	0.000462	0.0128	CbGeAlD
Gefitinib—MKNK2—testis—muscle cancer	0.00046	0.0127	CbGeAlD
Gefitinib—IRAK1—testis—muscle cancer	0.00046	0.0127	CbGeAlD
Gefitinib—MKNK1—testis—muscle cancer	0.000454	0.0126	CbGeAlD
Gefitinib—STK10—tendon—muscle cancer	0.000451	0.0125	CbGeAlD
Gefitinib—STK10—bone marrow—muscle cancer	0.000437	0.0121	CbGeAlD
Gefitinib—STK10—vagina—muscle cancer	0.000419	0.0116	CbGeAlD
Gefitinib—MAP2K5—tendon—muscle cancer	0.000403	0.0112	CbGeAlD
Gefitinib—STK10—head—muscle cancer	0.000387	0.0107	CbGeAlD
Gefitinib—ERBB3—Vinblastine—Vincristine—muscle cancer	0.000382	0.123	CbGdCrCtD
Gefitinib—CHEK2—Vinorelbine—Vincristine—muscle cancer	0.000376	0.121	CbGdCrCtD
Gefitinib—CHEK2—Teniposide—Etoposide—muscle cancer	0.000375	0.121	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—muscle cancer	0.000375	0.121	CbGdCrCtD
Gefitinib—MAP2K5—vagina—muscle cancer	0.000374	0.0104	CbGeAlD
Gefitinib—STK10—testis—muscle cancer	0.000374	0.0104	CbGeAlD
Gefitinib—Nail disorder—Methotrexate—muscle cancer	0.00036	0.00591	CcSEcCtD
Gefitinib—Mouth ulceration—Etoposide—muscle cancer	0.000352	0.00579	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.000352	0.00578	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.000352	0.00578	CcSEcCtD
Gefitinib—Gastric ulcer—Doxorubicin—muscle cancer	0.000347	0.00572	CcSEcCtD
Gefitinib—MAP2K5—head—muscle cancer	0.000346	0.00958	CbGeAlD
Gefitinib—Febrile neutropenia—Doxorubicin—muscle cancer	0.000336	0.00552	CcSEcCtD
Gefitinib—MAP2K5—testis—muscle cancer	0.000334	0.00925	CbGeAlD
Gefitinib—Interstitial lung disease—Methotrexate—muscle cancer	0.000329	0.00542	CcSEcCtD
Gefitinib—Eruption—Doxorubicin—muscle cancer	0.000328	0.0054	CcSEcCtD
Gefitinib—Dehydration—Vincristine—muscle cancer	0.000324	0.00534	CcSEcCtD
Gefitinib—Hypomagnesaemia—Doxorubicin—muscle cancer	0.000318	0.00523	CcSEcCtD
Gefitinib—ORM1—bone marrow—muscle cancer	0.000317	0.00879	CbGeAlD
Gefitinib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.000314	0.00517	CcSEcCtD
Gefitinib—Keratitis—Doxorubicin—muscle cancer	0.000311	0.00512	CcSEcCtD
Gefitinib—Nail disorder—Doxorubicin—muscle cancer	0.000311	0.00512	CcSEcCtD
Gefitinib—Pleural effusion—Methotrexate—muscle cancer	0.000305	0.00501	CcSEcCtD
Gefitinib—Pneumonia—Dactinomycin—muscle cancer	0.000303	0.00498	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.000298	0.00491	CcSEcCtD
Gefitinib—Seborrhoeic dermatitis—Doxorubicin—muscle cancer	0.000296	0.00487	CcSEcCtD
Gefitinib—Stomatitis—Dactinomycin—muscle cancer	0.000293	0.00482	CcSEcCtD
Gefitinib—Haemoptysis—Doxorubicin—muscle cancer	0.000273	0.00449	CcSEcCtD
Gefitinib—Weight decreased—Vincristine—muscle cancer	0.000273	0.00449	CcSEcCtD
Gefitinib—Pneumonia—Vincristine—muscle cancer	0.00027	0.00445	CcSEcCtD
Gefitinib—Hepatitis—Dactinomycin—muscle cancer	0.00027	0.00444	CcSEcCtD
Gefitinib—Proteinuria—Methotrexate—muscle cancer	0.000265	0.00437	CcSEcCtD
Gefitinib—Pleural effusion—Doxorubicin—muscle cancer	0.000264	0.00434	CcSEcCtD
Gefitinib—Stomatitis—Vincristine—muscle cancer	0.000262	0.00431	CcSEcCtD
Gefitinib—Protein urine present—Methotrexate—muscle cancer	0.000262	0.00431	CcSEcCtD
Gefitinib—Amblyopia—Doxorubicin—muscle cancer	0.000262	0.0043	CcSEcCtD
Gefitinib—CHEK2—Vinblastine—Vincristine—muscle cancer	0.000258	0.0833	CbGdCrCtD
Gefitinib—Erythema multiforme—Dactinomycin—muscle cancer	0.000255	0.0042	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.000254	0.00419	CcSEcCtD
Gefitinib—Rash pustular—Doxorubicin—muscle cancer	0.000253	0.00416	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000249	0.0041	CcSEcCtD
Gefitinib—Ulcer—Methotrexate—muscle cancer	0.000247	0.00406	CcSEcCtD
Gefitinib—Alopecia—Dactinomycin—muscle cancer	0.000239	0.00393	CcSEcCtD
Gefitinib—CYP1A1—renal system—muscle cancer	0.000239	0.00661	CbGeAlD
Gefitinib—Urinary tract disorder—Vincristine—muscle cancer	0.000238	0.00392	CcSEcCtD
Gefitinib—ALB—testis—muscle cancer	0.000238	0.00659	CbGeAlD
Gefitinib—Respiratory failure—Methotrexate—muscle cancer	0.000237	0.00391	CcSEcCtD
Gefitinib—Urethral disorder—Vincristine—muscle cancer	0.000237	0.00389	CcSEcCtD
Gefitinib—CYP3A5—renal system—muscle cancer	0.000233	0.00646	CbGeAlD
Gefitinib—Cystitis noninfective—Methotrexate—muscle cancer	0.000228	0.00375	CcSEcCtD
Gefitinib—Melaena—Methotrexate—muscle cancer	0.000228	0.00375	CcSEcCtD
Gefitinib—Cystitis—Methotrexate—muscle cancer	0.000225	0.0037	CcSEcCtD
Gefitinib—Cardiac disorder—Vincristine—muscle cancer	0.000224	0.00368	CcSEcCtD
Gefitinib—Pneumonia—Etoposide—muscle cancer	0.000219	0.0036	CcSEcCtD
Gefitinib—Angiopathy—Vincristine—muscle cancer	0.000219	0.0036	CcSEcCtD
Gefitinib—Infestation—Etoposide—muscle cancer	0.000218	0.00358	CcSEcCtD
Gefitinib—Infestation NOS—Etoposide—muscle cancer	0.000218	0.00358	CcSEcCtD
Gefitinib—Mediastinal disorder—Vincristine—muscle cancer	0.000218	0.00358	CcSEcCtD
Gefitinib—Anaemia—Dactinomycin—muscle cancer	0.000217	0.00358	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.000216	0.00355	CcSEcCtD
Gefitinib—CYP2C19—vagina—muscle cancer	0.000214	0.00594	CbGeAlD
Gefitinib—CYP1A1—cardiac atrium—muscle cancer	0.000214	0.00592	CbGeAlD
Gefitinib—Ulcer—Doxorubicin—muscle cancer	0.000213	0.00351	CcSEcCtD
Gefitinib—Alopecia—Vincristine—muscle cancer	0.000213	0.00351	CcSEcCtD
Gefitinib—Stomatitis—Etoposide—muscle cancer	0.000212	0.00349	CcSEcCtD
Gefitinib—Malaise—Dactinomycin—muscle cancer	0.000212	0.00349	CcSEcCtD
Gefitinib—Mouth ulceration—Methotrexate—muscle cancer	0.000211	0.00347	CcSEcCtD
Gefitinib—Bladder pain—Methotrexate—muscle cancer	0.000211	0.00347	CcSEcCtD
Gefitinib—Hepatobiliary disease—Etoposide—muscle cancer	0.000206	0.00339	CcSEcCtD
Gefitinib—Melaena—Doxorubicin—muscle cancer	0.000197	0.00324	CcSEcCtD
Gefitinib—Cystitis noninfective—Doxorubicin—muscle cancer	0.000197	0.00324	CcSEcCtD
Gefitinib—Thrombophlebitis—Methotrexate—muscle cancer	0.000196	0.00322	CcSEcCtD
Gefitinib—Cystitis—Doxorubicin—muscle cancer	0.000195	0.00321	CcSEcCtD
Gefitinib—Anaemia—Vincristine—muscle cancer	0.000194	0.00319	CcSEcCtD
Gefitinib—Urinary tract disorder—Etoposide—muscle cancer	0.000193	0.00318	CcSEcCtD
Gefitinib—Urethral disorder—Etoposide—muscle cancer	0.000192	0.00315	CcSEcCtD
Gefitinib—Infection—Dactinomycin—muscle cancer	0.000191	0.00314	CcSEcCtD
Gefitinib—ABCG2—bone marrow—muscle cancer	0.00019	0.00527	CbGeAlD
Gefitinib—Hepatic failure—Methotrexate—muscle cancer	0.000188	0.0031	CcSEcCtD
Gefitinib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000188	0.00309	CcSEcCtD
Gefitinib—Dry eye—Doxorubicin—muscle cancer	0.000187	0.00307	CcSEcCtD
Gefitinib—Erythema multiforme—Etoposide—muscle cancer	0.000185	0.00304	CcSEcCtD
Gefitinib—Anorexia—Dactinomycin—muscle cancer	0.000183	0.00301	CcSEcCtD
Gefitinib—Eye disorder—Etoposide—muscle cancer	0.000183	0.00301	CcSEcCtD
Gefitinib—Bladder pain—Doxorubicin—muscle cancer	0.000183	0.003	CcSEcCtD
Gefitinib—Mouth ulceration—Doxorubicin—muscle cancer	0.000183	0.003	CcSEcCtD
Gefitinib—ABCG2—vagina—muscle cancer	0.000182	0.00504	CbGeAlD
Gefitinib—Cardiac disorder—Etoposide—muscle cancer	0.000181	0.00298	CcSEcCtD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—muscle cancer	0.000181	0.0584	CbGdCrCtD
Gefitinib—Dermatitis exfoliative—Methotrexate—muscle cancer	0.000179	0.00295	CcSEcCtD
Gefitinib—Angiopathy—Etoposide—muscle cancer	0.000177	0.00292	CcSEcCtD
Gefitinib—Mediastinal disorder—Etoposide—muscle cancer	0.000176	0.0029	CcSEcCtD
Gefitinib—CYP3A4—renal system—muscle cancer	0.000175	0.00485	CbGeAlD
Gefitinib—Alopecia—Etoposide—muscle cancer	0.000173	0.00284	CcSEcCtD
Gefitinib—CYP1A1—vagina—muscle cancer	0.000173	0.00479	CbGeAlD
Gefitinib—CYP2D6—renal system—muscle cancer	0.000172	0.00477	CbGeAlD
Gefitinib—Infection—Vincristine—muscle cancer	0.00017	0.0028	CcSEcCtD
Gefitinib—Thrombophlebitis—Doxorubicin—muscle cancer	0.000169	0.00279	CcSEcCtD
Gefitinib—CYP3A5—vagina—muscle cancer	0.000169	0.00468	CbGeAlD
Gefitinib—Nervous system disorder—Vincristine—muscle cancer	0.000168	0.00277	CcSEcCtD
Gefitinib—Thrombocytopenia—Vincristine—muscle cancer	0.000168	0.00276	CcSEcCtD
Gefitinib—Decreased appetite—Dactinomycin—muscle cancer	0.000167	0.00274	CcSEcCtD
Gefitinib—Fatigue—Dactinomycin—muscle cancer	0.000165	0.00272	CcSEcCtD
Gefitinib—Pain—Dactinomycin—muscle cancer	0.000164	0.0027	CcSEcCtD
Gefitinib—ABCB1—embryo—muscle cancer	0.000164	0.00454	CbGeAlD
Gefitinib—Anorexia—Vincristine—muscle cancer	0.000163	0.00269	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—muscle cancer	0.000163	0.00268	CcSEcCtD
Gefitinib—ABCG2—testis—muscle cancer	0.000162	0.0045	CbGeAlD
Gefitinib—Eye pain—Doxorubicin—muscle cancer	0.000162	0.00267	CcSEcCtD
Gefitinib—Hypotension—Vincristine—muscle cancer	0.00016	0.00264	CcSEcCtD
Gefitinib—CYP1A1—head—muscle cancer	0.00016	0.00442	CbGeAlD
Gefitinib—Anaemia—Etoposide—muscle cancer	0.000157	0.00259	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000157	0.00258	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.000155	0.00256	CcSEcCtD
Gefitinib—Malaise—Etoposide—muscle cancer	0.000153	0.00252	CcSEcCtD
Gefitinib—Dermatitis bullous—Doxorubicin—muscle cancer	0.000153	0.00252	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000152	0.00251	CcSEcCtD
Gefitinib—Body temperature increased—Dactinomycin—muscle cancer	0.000152	0.0025	CcSEcCtD
Gefitinib—Abdominal pain—Dactinomycin—muscle cancer	0.000152	0.0025	CcSEcCtD
Gefitinib—Decreased appetite—Vincristine—muscle cancer	0.000149	0.00245	CcSEcCtD
Gefitinib—Cough—Etoposide—muscle cancer	0.000149	0.00244	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000148	0.00244	CcSEcCtD
Gefitinib—Fatigue—Vincristine—muscle cancer	0.000148	0.00243	CcSEcCtD
Gefitinib—Pain—Vincristine—muscle cancer	0.000147	0.00241	CcSEcCtD
Gefitinib—Constipation—Vincristine—muscle cancer	0.000147	0.00241	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000144	0.00237	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—muscle cancer	0.000143	0.00236	CcSEcCtD
Gefitinib—Hypersensitivity—Dactinomycin—muscle cancer	0.000141	0.00233	CcSEcCtD
Gefitinib—Gastrointestinal pain—Vincristine—muscle cancer	0.00014	0.00231	CcSEcCtD
Gefitinib—Infection—Etoposide—muscle cancer	0.000138	0.00227	CcSEcCtD
Gefitinib—Asthenia—Dactinomycin—muscle cancer	0.000138	0.00227	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—muscle cancer	0.000136	0.00224	CcSEcCtD
Gefitinib—Thrombocytopenia—Etoposide—muscle cancer	0.000136	0.00224	CcSEcCtD
Gefitinib—Body temperature increased—Vincristine—muscle cancer	0.000136	0.00223	CcSEcCtD
Gefitinib—Abdominal pain—Vincristine—muscle cancer	0.000136	0.00223	CcSEcCtD
Gefitinib—Skin disorder—Etoposide—muscle cancer	0.000135	0.00222	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—muscle cancer	0.000134	0.00221	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—muscle cancer	0.000133	0.00219	CcSEcCtD
Gefitinib—Anorexia—Etoposide—muscle cancer	0.000132	0.00218	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000132	0.00217	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000132	0.00217	CcSEcCtD
Gefitinib—Diarrhoea—Dactinomycin—muscle cancer	0.000131	0.00216	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—muscle cancer	0.000131	0.00216	CcSEcCtD
Gefitinib—Infestation—Methotrexate—muscle cancer	0.00013	0.00215	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—muscle cancer	0.00013	0.00215	CcSEcCtD
Gefitinib—Hypotension—Etoposide—muscle cancer	0.00013	0.00214	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000129	0.00213	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000129	0.00213	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—muscle cancer	0.000127	0.00209	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—muscle cancer	0.000127	0.00209	CcSEcCtD
Gefitinib—Hypersensitivity—Vincristine—muscle cancer	0.000126	0.00208	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—muscle cancer	0.000124	0.00205	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—muscle cancer	0.000124	0.00204	CcSEcCtD
Gefitinib—ABCB1—renal system—muscle cancer	0.000124	0.00343	CbGeAlD
Gefitinib—Dyspnoea—Etoposide—muscle cancer	0.000124	0.00204	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000123	0.00203	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—muscle cancer	0.000123	0.00202	CcSEcCtD
Gefitinib—Asthenia—Vincristine—muscle cancer	0.000123	0.00202	CcSEcCtD
Gefitinib—Vomiting—Dactinomycin—muscle cancer	0.000122	0.00201	CcSEcCtD
Gefitinib—Rash—Dactinomycin—muscle cancer	0.000121	0.00199	CcSEcCtD
Gefitinib—Decreased appetite—Etoposide—muscle cancer	0.000121	0.00199	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.00012	0.00197	CcSEcCtD
Gefitinib—Fatigue—Etoposide—muscle cancer	0.00012	0.00197	CcSEcCtD
Gefitinib—Pain—Etoposide—muscle cancer	0.000119	0.00195	CcSEcCtD
Gefitinib—Constipation—Etoposide—muscle cancer	0.000119	0.00195	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—muscle cancer	0.000118	0.00194	CcSEcCtD
Gefitinib—Diarrhoea—Vincristine—muscle cancer	0.000117	0.00193	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—muscle cancer	0.000117	0.00193	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—muscle cancer	0.000117	0.00193	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—muscle cancer	0.000116	0.0019	CcSEcCtD
Gefitinib—CYP2D6—head—muscle cancer	0.000115	0.00319	CbGeAlD
Gefitinib—Urethral disorder—Methotrexate—muscle cancer	0.000115	0.00189	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—muscle cancer	0.000115	0.00189	CcSEcCtD
Gefitinib—Nausea—Dactinomycin—muscle cancer	0.000114	0.00188	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—muscle cancer	0.000114	0.00187	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—muscle cancer	0.000114	0.00187	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—muscle cancer	0.000113	0.00186	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—muscle cancer	0.000113	0.00186	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000112	0.00184	CcSEcCtD
Gefitinib—CYP2D6—testis—muscle cancer	0.000111	0.00309	CbGeAlD
Gefitinib—Erythema multiforme—Methotrexate—muscle cancer	0.000111	0.00182	CcSEcCtD
Gefitinib—Urticaria—Etoposide—muscle cancer	0.00011	0.00182	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—muscle cancer	0.00011	0.00181	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—muscle cancer	0.00011	0.00181	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—muscle cancer	0.00011	0.00181	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—muscle cancer	0.00011	0.00181	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—muscle cancer	0.000109	0.0018	CcSEcCtD
Gefitinib—Vomiting—Vincristine—muscle cancer	0.000109	0.00179	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—muscle cancer	0.000109	0.00179	CcSEcCtD
Gefitinib—Rash—Vincristine—muscle cancer	0.000108	0.00178	CcSEcCtD
Gefitinib—Dermatitis—Vincristine—muscle cancer	0.000108	0.00178	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—muscle cancer	0.000108	0.00177	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000107	0.00176	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—muscle cancer	0.000107	0.00175	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—muscle cancer	0.000106	0.00175	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—muscle cancer	0.000106	0.00174	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—muscle cancer	0.000103	0.0017	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—muscle cancer	0.000102	0.00168	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—muscle cancer	0.000102	0.00168	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—muscle cancer	0.000102	0.00168	CcSEcCtD
Gefitinib—Nausea—Vincristine—muscle cancer	0.000102	0.00168	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—muscle cancer	0.000101	0.00167	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—muscle cancer	0.000101	0.00167	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—muscle cancer	0.0001	0.00165	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—muscle cancer	9.99e-05	0.00164	CcSEcCtD
Gefitinib—Asthenia—Etoposide—muscle cancer	9.97e-05	0.00164	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—muscle cancer	9.94e-05	0.00164	CcSEcCtD
Gefitinib—Pruritus—Etoposide—muscle cancer	9.83e-05	0.00162	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—muscle cancer	9.59e-05	0.00158	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—muscle cancer	9.5e-05	0.00156	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—muscle cancer	9.48e-05	0.00156	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—muscle cancer	9.42e-05	0.00155	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—muscle cancer	9.41e-05	0.00155	CcSEcCtD
Gefitinib—ABCB1—bone marrow—muscle cancer	9.37e-05	0.0026	CbGeAlD
Gefitinib—Angiopathy—Doxorubicin—muscle cancer	9.2e-05	0.00151	CcSEcCtD
Gefitinib—Malaise—Methotrexate—muscle cancer	9.19e-05	0.00151	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—muscle cancer	9.14e-05	0.0015	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—muscle cancer	9.06e-05	0.00149	CcSEcCtD
Gefitinib—ABCB1—vagina—muscle cancer	8.97e-05	0.00249	CbGeAlD
Gefitinib—Alopecia—Doxorubicin—muscle cancer	8.96e-05	0.00147	CcSEcCtD
Gefitinib—Cough—Methotrexate—muscle cancer	8.9e-05	0.00146	CcSEcCtD
Gefitinib—Vomiting—Etoposide—muscle cancer	8.83e-05	0.00145	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—muscle cancer	8.83e-05	0.00145	CcSEcCtD
Gefitinib—Rash—Etoposide—muscle cancer	8.76e-05	0.00144	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—muscle cancer	8.75e-05	0.00144	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.62e-05	0.00142	CcSEcCtD
Gefitinib—ABCB1—head—muscle cancer	8.29e-05	0.0023	CbGeAlD
Gefitinib—Infection—Methotrexate—muscle cancer	8.27e-05	0.00136	CcSEcCtD
Gefitinib—Nausea—Etoposide—muscle cancer	8.25e-05	0.00136	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—muscle cancer	8.16e-05	0.00134	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—muscle cancer	8.16e-05	0.00134	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—muscle cancer	8.15e-05	0.00134	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—muscle cancer	8.08e-05	0.00133	CcSEcCtD
Gefitinib—ABCB1—testis—muscle cancer	8.01e-05	0.00222	CbGeAlD
Gefitinib—Malaise—Doxorubicin—muscle cancer	7.96e-05	0.00131	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—muscle cancer	7.93e-05	0.0013	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—muscle cancer	7.77e-05	0.00128	CcSEcCtD
Gefitinib—Cough—Doxorubicin—muscle cancer	7.7e-05	0.00127	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.46e-05	0.00123	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—muscle cancer	7.42e-05	0.00122	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—muscle cancer	7.35e-05	0.00121	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—muscle cancer	7.23e-05	0.00119	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—muscle cancer	7.18e-05	0.00118	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—muscle cancer	7.17e-05	0.00118	CcSEcCtD
Gefitinib—Infection—Doxorubicin—muscle cancer	7.16e-05	0.00118	CcSEcCtD
Gefitinib—Pain—Methotrexate—muscle cancer	7.11e-05	0.00117	CcSEcCtD
Gefitinib—Shock—Doxorubicin—muscle cancer	7.09e-05	0.00117	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—muscle cancer	7.06e-05	0.00116	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—muscle cancer	7.05e-05	0.00116	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—muscle cancer	7e-05	0.00115	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—muscle cancer	6.87e-05	0.00113	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—muscle cancer	6.8e-05	0.00112	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—muscle cancer	6.73e-05	0.00111	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—muscle cancer	6.61e-05	0.00109	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—muscle cancer	6.58e-05	0.00108	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—muscle cancer	6.58e-05	0.00108	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—muscle cancer	6.42e-05	0.00106	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—muscle cancer	6.26e-05	0.00103	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	6.22e-05	0.00102	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—muscle cancer	6.21e-05	0.00102	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—muscle cancer	6.16e-05	0.00101	CcSEcCtD
Gefitinib—Pain—Doxorubicin—muscle cancer	6.16e-05	0.00101	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—muscle cancer	6.13e-05	0.00101	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—muscle cancer	5.97e-05	0.000982	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—muscle cancer	5.89e-05	0.000969	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—muscle cancer	5.89e-05	0.000968	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—muscle cancer	5.72e-05	0.000941	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—muscle cancer	5.69e-05	0.000937	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—muscle cancer	5.69e-05	0.000937	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—muscle cancer	5.69e-05	0.000936	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—muscle cancer	5.31e-05	0.000873	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—muscle cancer	5.29e-05	0.00087	CcSEcCtD
Gefitinib—Rash—Methotrexate—muscle cancer	5.25e-05	0.000863	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—muscle cancer	5.24e-05	0.000862	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—muscle cancer	5.17e-05	0.00085	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—muscle cancer	5.1e-05	0.000838	CcSEcCtD
Gefitinib—Nausea—Methotrexate—muscle cancer	4.94e-05	0.000813	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—muscle cancer	4.93e-05	0.000811	CcSEcCtD
Gefitinib—EGFR—Signaling by FGFR—KIT—muscle cancer	4.74e-05	0.000944	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—KIT—muscle cancer	4.72e-05	0.00094	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—KIT—muscle cancer	4.69e-05	0.000935	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD34—muscle cancer	4.69e-05	0.000935	CbGpPWpGaD
Gefitinib—MAP2K5—Focal Adhesion—VEGFA—muscle cancer	4.65e-05	0.000926	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MED12—muscle cancer	4.65e-05	0.000925	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—PTGS2—muscle cancer	4.64e-05	0.000924	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	4.63e-05	0.000922	CbGpPWpGaD
Gefitinib—Vomiting—Doxorubicin—muscle cancer	4.58e-05	0.000753	CcSEcCtD
Gefitinib—IRAK1—Innate Immune System—FOXO4—muscle cancer	4.56e-05	0.000908	CbGpPWpGaD
Gefitinib—EPHA6—Axon guidance—VEGFA—muscle cancer	4.55e-05	0.000907	CbGpPWpGaD
Gefitinib—Rash—Doxorubicin—muscle cancer	4.54e-05	0.000747	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—muscle cancer	4.54e-05	0.000747	CcSEcCtD
Gefitinib—IRAK1—Signaling by NGF—KIT—muscle cancer	4.5e-05	0.000896	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—KIT—muscle cancer	4.42e-05	0.00088	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	4.42e-05	0.00088	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—KIT—muscle cancer	4.42e-05	0.00088	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling by NGF—MDM2—muscle cancer	4.42e-05	0.00088	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—KIT—muscle cancer	4.38e-05	0.000872	CbGpPWpGaD
Gefitinib—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	4.35e-05	0.000866	CbGpPWpGaD
Gefitinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	4.34e-05	0.000865	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—KIT—muscle cancer	4.34e-05	0.000864	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—KIT—muscle cancer	4.32e-05	0.00086	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HMGA1—muscle cancer	4.31e-05	0.000859	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD34—muscle cancer	4.31e-05	0.000858	CbGpPWpGaD
Gefitinib—Nausea—Doxorubicin—muscle cancer	4.28e-05	0.000704	CcSEcCtD
Gefitinib—ERBB3—Signaling by NGF—MDM2—muscle cancer	4.26e-05	0.000848	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—TP53—muscle cancer	4.25e-05	0.000847	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—MDM2—muscle cancer	4.2e-05	0.000836	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—MDM2—muscle cancer	4.17e-05	0.000831	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—KIT—muscle cancer	4.09e-05	0.000814	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PTCH1—muscle cancer	4.05e-05	0.000806	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—FOXO1—muscle cancer	4.04e-05	0.000806	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—CDKN2A—muscle cancer	4.02e-05	0.0008	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—FOXO4—muscle cancer	4e-05	0.000797	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling of activated FGFR—MDM2—muscle cancer	3.99e-05	0.000795	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	3.95e-05	0.000787	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—FOXO1—muscle cancer	3.95e-05	0.000787	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—MDM2—muscle cancer	3.93e-05	0.000783	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	3.91e-05	0.000779	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD34—muscle cancer	3.91e-05	0.000778	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—MDM2—muscle cancer	3.9e-05	0.000776	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—FOXO1—muscle cancer	3.88e-05	0.000774	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—TP53—muscle cancer	3.88e-05	0.000772	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—KIT—muscle cancer	3.87e-05	0.00077	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—FOXO4—muscle cancer	3.87e-05	0.00077	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle, Mitotic—CDKN2A—muscle cancer	3.85e-05	0.000767	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—MDM2—muscle cancer	3.75e-05	0.000747	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—MDM2—muscle cancer	3.73e-05	0.000744	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3.73e-05	0.000743	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—MDM2—muscle cancer	3.71e-05	0.00074	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—MDM2—muscle cancer	3.7e-05	0.000737	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways in Glioblastoma—TP53—muscle cancer	3.69e-05	0.000736	CbGpPWpGaD
Gefitinib—MKNK1—Disease—FOXO1—muscle cancer	3.67e-05	0.000731	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	3.64e-05	0.000726	CbGpPWpGaD
Gefitinib—ERBB3—Disease—ENO2—muscle cancer	3.61e-05	0.00072	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—MDM2—muscle cancer	3.54e-05	0.000706	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—FOXO4—muscle cancer	3.48e-05	0.000693	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—MDM2—muscle cancer	3.48e-05	0.000693	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—MDM2—muscle cancer	3.48e-05	0.000693	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	3.48e-05	0.000693	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—MDM2—muscle cancer	3.45e-05	0.000687	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—CDKN2A—muscle cancer	3.44e-05	0.000686	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CNR1—muscle cancer	3.42e-05	0.000681	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—MDM2—muscle cancer	3.42e-05	0.000681	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—MDM2—muscle cancer	3.4e-05	0.000678	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KIDINS220—muscle cancer	3.39e-05	0.000676	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	3.38e-05	0.000673	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—FOXO1—muscle cancer	3.37e-05	0.000671	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—MDM2—muscle cancer	3.34e-05	0.000665	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HMGA1—muscle cancer	3.28e-05	0.000654	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.27e-05	0.000652	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—VEGFA—muscle cancer	3.25e-05	0.000647	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—ANGPT2—muscle cancer	3.22e-05	0.000642	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—MDM2—muscle cancer	3.22e-05	0.000641	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—FOXO4—muscle cancer	3.19e-05	0.000636	CbGpPWpGaD
Gefitinib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	3.18e-05	0.000633	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3.15e-05	0.000629	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PTCH1—muscle cancer	3.15e-05	0.000627	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—KIT—muscle cancer	3.08e-05	0.000614	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	3.08e-05	0.000614	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—FH—muscle cancer	3.05e-05	0.000608	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—FOXO4—muscle cancer	3.05e-05	0.000607	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—MDM2—muscle cancer	3.04e-05	0.000607	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	3.04e-05	0.000605	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—KIT—muscle cancer	3.01e-05	0.000599	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	3e-05	0.000597	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KIT—muscle cancer	2.96e-05	0.00059	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—FOXO1—muscle cancer	2.96e-05	0.000589	CbGpPWpGaD
Gefitinib—ERBB3—Disease—FOXO4—muscle cancer	2.95e-05	0.000587	CbGpPWpGaD
Gefitinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	2.93e-05	0.000585	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—FOXO4—muscle cancer	2.93e-05	0.000583	CbGpPWpGaD
Gefitinib—ALB—Platelet degranulation—VEGFA—muscle cancer	2.87e-05	0.000572	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—FOXO1—muscle cancer	2.85e-05	0.000569	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KIT—muscle cancer	2.8e-05	0.000557	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IGF2—muscle cancer	2.79e-05	0.000556	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TP53—muscle cancer	2.76e-05	0.00055	CbGpPWpGaD
Gefitinib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	2.74e-05	0.000545	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—FOXO4—muscle cancer	2.71e-05	0.000539	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CNR1—muscle cancer	2.66e-05	0.000529	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—FOXO4—muscle cancer	2.66e-05	0.000529	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.62e-05	0.000522	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD34—muscle cancer	2.61e-05	0.000521	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—FOXO1—muscle cancer	2.57e-05	0.000512	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KIT—muscle cancer	2.57e-05	0.000511	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—FOXO1—muscle cancer	2.55e-05	0.000508	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	2.54e-05	0.000506	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TP53—muscle cancer	2.53e-05	0.000504	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—VEGFA—muscle cancer	2.5e-05	0.000497	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTCH1—muscle cancer	2.49e-05	0.000496	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.49e-05	0.000495	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—MDM2—muscle cancer	2.43e-05	0.000484	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—TP53—muscle cancer	2.41e-05	0.00048	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTCH1—muscle cancer	2.4e-05	0.000478	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.39e-05	0.000476	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—MDM2—muscle cancer	2.37e-05	0.000472	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—FOXO1—muscle cancer	2.36e-05	0.000469	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—MDM2—muscle cancer	2.33e-05	0.000464	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—TP53—muscle cancer	2.27e-05	0.000451	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PTCH1—muscle cancer	2.26e-05	0.00045	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—FOXO1—muscle cancer	2.25e-05	0.000449	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KIT—muscle cancer	2.25e-05	0.000449	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—TP53—muscle cancer	2.24e-05	0.000445	CbGpPWpGaD
Gefitinib—MKNK1—Disease—MDM2—muscle cancer	2.2e-05	0.000439	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—FH—muscle cancer	2.19e-05	0.000436	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KIT—muscle cancer	2.18e-05	0.000433	CbGpPWpGaD
Gefitinib—ERBB3—Disease—FOXO1—muscle cancer	2.18e-05	0.000433	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IGF2—muscle cancer	2.17e-05	0.000433	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—FOXO1—muscle cancer	2.16e-05	0.000431	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.15e-05	0.000427	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—FOXO4—muscle cancer	2.14e-05	0.000426	CbGpPWpGaD
Gefitinib—MKNK1—Disease—PTGS2—muscle cancer	2.12e-05	0.000423	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CNR1—muscle cancer	2.1e-05	0.000418	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TP53—muscle cancer	2.08e-05	0.000415	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—FH—muscle cancer	2.07e-05	0.000412	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—FOXO4—muscle cancer	2.06e-05	0.000411	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CNR1—muscle cancer	2.02e-05	0.000403	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—MDM2—muscle cancer	2.02e-05	0.000403	CbGpPWpGaD
Gefitinib—EGFR—Disease—ENO2—muscle cancer	2.01e-05	0.000401	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—FOXO1—muscle cancer	2e-05	0.000398	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTCH1—muscle cancer	2e-05	0.000398	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—FOXO1—muscle cancer	1.96e-05	0.000391	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KIT—muscle cancer	1.96e-05	0.00039	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.96e-05	0.00039	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—TP53—muscle cancer	1.92e-05	0.000382	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CNR1—muscle cancer	1.91e-05	0.00038	CbGpPWpGaD
Gefitinib—ALB—Metabolism—FH—muscle cancer	1.88e-05	0.000375	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.88e-05	0.000374	CbGpPWpGaD
Gefitinib—EGFR—Disease—HMGA1—muscle cancer	1.83e-05	0.000364	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KIT—muscle cancer	1.8e-05	0.000358	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FOXO4—muscle cancer	1.78e-05	0.000354	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—MDM2—muscle cancer	1.77e-05	0.000353	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MED12—muscle cancer	1.72e-05	0.000344	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FOXO4—muscle cancer	1.72e-05	0.000342	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IGF2—muscle cancer	1.72e-05	0.000342	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KIT—muscle cancer	1.72e-05	0.000342	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MDM2—muscle cancer	1.71e-05	0.000341	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—FH—muscle cancer	1.69e-05	0.000337	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CNR1—muscle cancer	1.69e-05	0.000336	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KIT—muscle cancer	1.66e-05	0.00033	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IGF2—muscle cancer	1.66e-05	0.00033	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.65e-05	0.000329	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTGS2—muscle cancer	1.65e-05	0.000329	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—FH—muscle cancer	1.65e-05	0.000329	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KIT—muscle cancer	1.65e-05	0.000328	CbGpPWpGaD
Gefitinib—EGFR—Disease—FOXO4—muscle cancer	1.64e-05	0.000327	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—VEGFA—muscle cancer	1.63e-05	0.000324	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.59e-05	0.000317	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—FOXO1—muscle cancer	1.58e-05	0.000315	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ENO2—muscle cancer	1.57e-05	0.000313	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IGF2—muscle cancer	1.57e-05	0.000312	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—FH—muscle cancer	1.56e-05	0.00031	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MDM2—muscle cancer	1.54e-05	0.000307	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—FH—muscle cancer	1.54e-05	0.000307	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KIT—muscle cancer	1.52e-05	0.000303	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—FOXO1—muscle cancer	1.52e-05	0.000303	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KIT—muscle cancer	1.49e-05	0.000298	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MDM2—muscle cancer	1.41e-05	0.000282	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IGF2—muscle cancer	1.38e-05	0.000275	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MDM2—muscle cancer	1.35e-05	0.000269	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTCH1—muscle cancer	1.34e-05	0.000266	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FOXO1—muscle cancer	1.31e-05	0.000261	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MDM2—muscle cancer	1.31e-05	0.00026	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—MDM2—muscle cancer	1.3e-05	0.000259	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.27e-05	0.000254	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FOXO1—muscle cancer	1.27e-05	0.000253	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTGS2—muscle cancer	1.26e-05	0.000251	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.25e-05	0.00025	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MED12—muscle cancer	1.24e-05	0.000246	CbGpPWpGaD
Gefitinib—EGFR—Disease—FOXO1—muscle cancer	1.21e-05	0.000241	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KIT—muscle cancer	1.2e-05	0.00024	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MDM2—muscle cancer	1.2e-05	0.000239	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MDM2—muscle cancer	1.18e-05	0.000235	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—VEGFA—muscle cancer	1.17e-05	0.000233	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MED12—muscle cancer	1.17e-05	0.000233	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—VEGFA—muscle cancer	1.16e-05	0.000231	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KIT—muscle cancer	1.16e-05	0.000231	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FOXO4—muscle cancer	1.15e-05	0.000229	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CNR1—muscle cancer	1.13e-05	0.000225	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ENO2—muscle cancer	1.13e-05	0.000224	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ENO2—muscle cancer	1.06e-05	0.000212	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MED12—muscle cancer	1.06e-05	0.000212	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—FH—muscle cancer	1.02e-05	0.000203	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KIT—muscle cancer	9.99e-06	0.000199	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ENO2—muscle cancer	9.7e-06	0.000193	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KIT—muscle cancer	9.66e-06	0.000193	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MED12—muscle cancer	9.55e-06	0.00019	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	9.48e-06	0.000189	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	9.48e-06	0.000189	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MED12—muscle cancer	9.33e-06	0.000186	CbGpPWpGaD
Gefitinib—EGFR—Disease—KIT—muscle cancer	9.23e-06	0.000184	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF2—muscle cancer	9.21e-06	0.000184	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MDM2—muscle cancer	9.14e-06	0.000182	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—muscle cancer	9.11e-06	0.000181	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—muscle cancer	8.85e-06	0.000176	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MED12—muscle cancer	8.79e-06	0.000175	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MED12—muscle cancer	8.71e-06	0.000174	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ENO2—muscle cancer	8.71e-06	0.000174	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO2—muscle cancer	8.5e-06	0.000169	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FOXO1—muscle cancer	8.48e-06	0.000169	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.32e-06	0.000166	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO2—muscle cancer	8.01e-06	0.00016	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO2—muscle cancer	7.94e-06	0.000158	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MDM2—muscle cancer	7.87e-06	0.000157	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MDM2—muscle cancer	7.61e-06	0.000152	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	7.59e-06	0.000151	CbGpPWpGaD
Gefitinib—EGFR—Disease—MDM2—muscle cancer	7.27e-06	0.000145	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	7.2e-06	0.000143	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—muscle cancer	7.01e-06	0.00014	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—muscle cancer	6.94e-06	0.000138	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—muscle cancer	6.88e-06	0.000137	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.81e-06	0.000136	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—muscle cancer	6.57e-06	0.000131	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KIT—muscle cancer	6.46e-06	0.000129	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.21e-06	0.000124	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—muscle cancer	5.78e-06	0.000115	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MED12—muscle cancer	5.75e-06	0.000114	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—muscle cancer	5.48e-06	0.000109	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—muscle cancer	5.44e-06	0.000108	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—muscle cancer	5.24e-06	0.000104	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—muscle cancer	5.24e-06	0.000104	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—muscle cancer	5.09e-06	0.000101	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—muscle cancer	4.96e-06	9.88e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—muscle cancer	4.37e-06	8.7e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—muscle cancer	3.92e-06	7.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—muscle cancer	3.86e-06	7.7e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—muscle cancer	3.71e-06	7.39e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—muscle cancer	3.38e-06	6.73e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—muscle cancer	3.03e-06	6.04e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—muscle cancer	2.96e-06	5.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—muscle cancer	2.92e-06	5.82e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—muscle cancer	2.79e-06	5.56e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—muscle cancer	2.77e-06	5.51e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—muscle cancer	1.82e-06	3.63e-05	CbGpPWpGaD
